Evidence map›Paper›PMID 35893830›Full record

ArticleVaccines2022

Clinical and Virological Features of Patients Hospitalized with Different Types of COVID-19 Vaccination in Mexico City.

Alejandra Hernández-Terán, Pamela Garcíadiego-Fossas, Marco Villanueva-Reza, Celia Boukadida, Blanca Taboada, Eduardo Porras, Victor Ahumada-Topete, Kathia Elizabeth Tapia-Diaz, Margarita Matías-Florentino, Marissa Pérez-García and 11 more

Abstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Alejandra Hernández-TeránDepartamento de Investigación en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.
Pamela Garcíadiego-FossasDepartamento de Unidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.
Marco Villanueva-RezaDepartamento de Unidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.ORCID 0000-0001-5690-2941
Celia BoukadidaCentro de Investigación en Enfermedades Infecciosas, CIENI, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.ORCID 0000-0002-1744-0083
Blanca TaboadaDepartamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca 62210, Mexico.ORCID 0000-0003-1896-5962
Eduardo PorrasDepartamento de Unidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.ORCID 0000-0003-2589-8497
Victor Ahumada-TopeteDepartamento de Unidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.
Kathia Elizabeth Tapia-DiazCentro de Investigación en Enfermedades Infecciosas, CIENI, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.
Margarita Matías-FlorentinoCentro de Investigación en Enfermedades Infecciosas, CIENI, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.
Marissa Pérez-GarcíaCentro de Investigación en Enfermedades Infecciosas, CIENI, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.
Santiago Ávila-RíosCentro de Investigación en Enfermedades Infecciosas, CIENI, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.
Fidencio Mejía-NepomucenoDepartamento de Investigación en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.
Ricardo Serna-MuñozDepartamento de Investigación en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.
Fortunato Juárez-HernándezDepartamento de Imagenología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.ORCID 0000-0001-8361-3512
María Eugenia Jiménez-CoronaDepartamento de Epidemiología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0002-3804-9761
Eduardo Becerril-VargasLaboratorio de Microbiología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.
Omar BarretoCoordinación de Atención Médica, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.
Jose Arturo Martínez-OrozcoLaboratorio de Microbiología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.ORCID 0000-0002-9708-5631
Rogelio Pérez-PadillaDepartamento de Investigación en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.
Carlos F AriasDepartamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca 62210, Mexico.
Joel Armando Vázquez-PérezDepartamento de Investigación en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER, Mexico City 14080, Mexico.ORCID 0000-0002-8508-3698

Funding

AHF Global Public Health Institute, University of Miami Genomic surveillance for SARS-CoV-2 variants in MexicoConsejo Nacional de Ciencia y Tecnología Caracterizacion de la diversidad viral y bacterianaSECTEI 057
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) vaccines effectively protect against severe disease and death. However, the impact of the vaccine used, viral variants, and host factors on disease severity remain poorly understood. This work aimed to compare COVID-19 clinical presentations and outcomes in vaccinated and unvaccinated patients in Mexico City. From March to September 2021, clinical, demographic characteristics, and viral variants were obtained from 1014 individuals with a documented SARS-CoV-2 infection. We compared unvaccinated, partially vaccinated, and fully vaccinated patients, stratifying by age groups. We also fitted multivariate statistical models to evaluate the impact of vaccination status, SARS-CoV-2 lineages, vaccine types, and clinical parameters. Most hospitalized patients were unvaccinated. In patients over 61 years old, mortality was significantly higher in unvaccinated compared to fully vaccinated individuals. In patients aged 31 to 60 years, vaccinated patients were more likely to be outpatients (46%) than unvaccinated individuals (6.1%). We found immune disease and age above 61 years old to be risk factors, while full vaccination was found to be the most protective factor against in-hospital death. This study suggests that vaccination is essential to reduce mortality in a comorbid population such as that of Mexico.

Indexed as

comorbidities in COVID-19COVID-19COVID-19 severitySARS-CoV-2 lineagesvaccination schemes

Identifiers

PMID35893830
PMCPMC9330015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.